Assembly Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

• Assembly Biosciences Inc reported a quarterly adjusted loss of 93 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -72 cents. The mean expectation of five analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -80 cents to -26 cents per share.

• Revenue fell 72.6% to $2.96 million from a year ago; analysts expected $7.26 million.

• Assembly Biosciences Inc's reported EPS for the quarter was a loss of 93 cents​.

• The company reported a quarterly loss of $20.26 million.

• Assembly Biosciences Inc shares had fallen by 4.8% this quarter and lost 34.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 26.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Assembly Biosciences Inc is $52.00, about 57% above its last closing price of $22.37

This summary was machine generated from LSEG data November 12 at 09:49 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)